NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-184249

Registered date:13/12/2018

A repeatedly applied study of BBI-4000 in patients with primary hyperhidrosis

Basic Information

Recruitment status complete
Health condition(s) or Problem(s) studiedPrimary axillary hyperhidrosis
Date of first enrollment19/1/2019
Target sample size25
Countries of recruitmentJapan
Study typeINTERVENTIONAL
Intervention(s)Intervention name : BBI-4000 INN of the intervention : sofpironium bromide Dosage And administration of the intervention : Once per day Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -

Outcome(s)

Primary Outcomepharmacokinetics Plasma BBI-4000 level
Secondary Outcomesafety Adverse event

Key inclusion & exclusion criteria

Age minimum20
Age maximum65
GenderBOTH
Include criteriaPatients diagnosed as primary axillary hyperhidrosis
Exclude criteriaSecondary hyperhidrosis

Related Information

Contact

public contact
Name KAKEN PHARMACEUTICAL, CO., LTD. Clinical Development Department
Address
Telephone
E-mail akamatsu_motoki@kaken.co.jp
Affiliation
scientific contact
Name KAKEN PHARMACEUTICAL, CO., LTD. Clinical Development Department
Address
Telephone
E-mail akamatsu_motoki@kaken.co.jp
Affiliation